^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Ogsiveo (nirogacestat)

    i
    Company:
    SpringWorks Therap
    Drug class:
    γ-secretase inhibitor
    Related drugs:
    Apply
    A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment (NCT05556798)
    Phase 1
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    05/07/2024
    Initiation :
    10/04/2022
    Primary completion :
    10/01/2026
    Completion :
    10/01/2026
    SDC1
    |
    pomalidomide • Blenrep (belantamab mafodotin-blmf) • Ogsiveo (nirogacestat)
    A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery (NCT04195399)
    Phase 2
    Children's Oncology Group
    Active, not recruiting
    Last update posted :
    03/06/2024
    Initiation :
    10/07/2020
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    CD8 • CTNNB1 • APC • CD4
    |
    APC mutation
    |
    Ogsiveo (nirogacestat)
    A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma (NCT05573802)
    Phase 1/2
    Hellenic Society of Hematology
    Recruiting
    Last update posted :
    10/24/2023
    Initiation :
    07/14/2023
    Primary completion :
    10/31/2026
    Completion :
    10/31/2026
    CD4
    |
    lenalidomide • dexamethasone • Blenrep (belantamab mafodotin-blmf) • Ogsiveo (nirogacestat)
    A Trial In Patients With Advanced Cancer And Leukemia (NCT00878189)
    Phase 1
    Pfizer
    Completed
    Last update posted :
    11/12/2019
    Initiation :
    06/25/2009
    Primary completion :
    01/10/2013
    Completion :
    11/22/2016
    NOTCH1 • NICD • HES4
    |
    NOTCH1 expression
    |
    Ogsiveo (nirogacestat)
    Biomarker Research Study for PF-03084014 in cHEmoresistant Triple-negative Breast cAncer (RHEA) (NCT02338531)
    Phase 2
    Jules Bordet Institute
    Withdrawn
    Last update posted :
    04/29/2016
    Initiation :
    06/01/2015
    Primary completion :
    09/01/2018
    Completion :
    12/01/2018
    HER-2 • HES4
    |
    Ogsiveo (nirogacestat)
    Gamma Secretase Inhibitor PF-03084014 in Treating Patients With AIDS-Associated Kaposi Sarcoma (NCT02137564)
    Phase 2
    AIDS Malignancy Consortium
    Withdrawn
    Last update posted :
    07/23/2015
    Initiation :
    07/01/2015
    Primary completion :
    07/01/2015
    Completion :
    07/01/2015
    CD4
    |
    Ogsiveo (nirogacestat)